m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00041)
Name
CD666
Synonyms
CD-666; CD 666
    Click to Show/Hide
Status
Investigative
Structure
Formula
C24H28O3
InChI
1S/C24H28O3/c1-23(2)13-14-24(3,4)20-15-18(10-11-19(20)23)21(25)12-7-16-5-8-17(9-6-16)22(26)27/h5-12,15,21,25H,13-14H2,1-4H3,(H,26,27)/b12-7+
InChIKey
QCSYBKHFYYISTQ-KPKJPENVSA-N
PubChem CID
10090192
TTD Drug ID
D0F8CC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Retinoic acid receptor alpha (RARA)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Retinoic acid receptor alpha (RARA) is a therapeutic target for CD666. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CD666 through regulating the expression of Retinoic acid receptor alpha (RARA). [1], [2]
References
Ref 1 FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub 2016 Dec 22.
Ref 2 Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids. Gen Comp Endocrinol. 2009 Sep 15;163(3):285-91. doi: 10.1016/j.ygcen.2009.04.025. Epub 2009 May 3.